Inspyr Therapeutics, Inc. (NSPX) financial statements (2021 and earlier)

Company profile

Business Address 2511 N LOOP 1604 W
SAN ANTONIO, TX 78258
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 001224
Cash and cash equivalents 001224
Restricted cash and investments 0     
Prepaid expense  00000
Total current assets: 001334
Noncurrent Assets
Property, plant and equipment 000000
Intangible assets, net (including goodwill) 000000
Intangible assets, net (excluding goodwill) 000000
Other undisclosed noncurrent assets   0000
Total noncurrent assets: 000000
TOTAL ASSETS: 001334
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 442344
Accounts payable 221111
Accrued liabilities 220211
Employee-related liabilities     11
Debt 32  00
Derivative instruments and hedges, liabilities 2331  
Other undisclosed current liabilities     (1)(1)
Total current liabilities: 994533
Noncurrent Liabilities
Total liabilities: 994533
Stockholders' equity
Stockholders' equity attributable to parent, including: (8)(9)(3)(2)01
Common stock 00 000
Additional paid in capital 515145433934
Accumulated deficit (60)(60)(49)(45)  
Other undisclosed stockholders' equity attributable to parent     (39)(32)
Total stockholders' equity: (8)(9)(3)(2)01
TOTAL LIABILITIES AND EQUITY: 001334

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Operating expenses (1)(6)(3)(6)(7)(6)
Operating loss: (1)(6)(3)(6)(7)(6)
Interest and debt expense 00  0 
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes 1(5)(0)0 1
Net loss attributable to parent: (0)(11)(4)(6)(7)(5)
Preferred stock dividends and other adjustments (0)(2)    
Net loss available to common stockholders, diluted: (0)(13)(4)(6)(7)(5)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss: (0)(11)(4)(6)(7)(5)
Comprehensive loss, net of tax, attributable to parent: (0)(11)(4)(6)(7)(5)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: